mobile menu icon

Bristows advises NuCana plc on Nasdaq IPO



NuCana plc (Nasdaq:NCNA) is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its ProTide™ technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.

NuCana closed its initial public offering of American Depositary Shares on 2 October 2017 raising total gross proceeds of approximately $114 million (before deducting discounts and commissions). 

Bristows advised NuCana on the UK aspects of its initial public offering.  The members of the corporate team involved on this transaction included:

Partner Miranda Cass and Senior Associate Julia Cockcroft provided UK tax advice to NuCana.

Sign up for newsletters

If you would like to subscribe to regular Bristows publications, please click on the Sign up button below to complete our short registration form.

Share to: